Europe
At the six-month mark, 68% of participants reported at least one persistent symptom, which fell to 49% after one year.
Biopharma companies and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
Scientists from Oxford University may have found the key to treating endometriosis, a disease that affects around 176 million women worldwide.
Funds will be used to advance the clinical development of Cardior’s lead program, CDR132L, an oligonucleotide-based ncRNA inhibitor targeting micro-RNA-132.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Novartis reported that its Kymriah failed to hit its primary endpoint in the Phase III BELINDA trial in aggressive B-cell non-Hodgkin lymphoma after relapse or lack of response to first-line treatment.
It was another busy week in clinical trial news. Here’s a look.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Global biopharma and life sciences companies provide updates to their businesses and pipelines.
PRESS RELEASES